Generic placeholder image

Current Molecular Medicine


ISSN (Print): 1566-5240
ISSN (Online): 1875-5666

Mammalian Target of Rapamycin as a Therapeutic Target in Leukemia

Author(s): Francis J. Giles and Maher Albitar

Volume 5, Issue 7, 2005

Page: [653 - 661] Pages: 9

DOI: 10.2174/156652405774641034

Price: $65


Reflecting its critical role in integrating cell growth and division with the cellular nutritional environment, the mammalian target of rapamycin *(mTOR) is a highly conserved downstream effector of the phosphatidylinositol 3-kinase (PI3K)/Akt (protein kinase B) signaling pathway. mTOR activates both the 40S ribosomal protein S6 kinase (p70s6k) and the eukaryotic initiation factor 4E-binding protein-1. As a consequence of inhibiting its downstream messengers, mTOR inhibitors prevent cyclindependent kinase (CDK) activation, inhibit retinoblastoma protein phosphorylation, and accelerate the turnover of cyclin D1, leading to a deficiency of active CDK4/cyclin D1 complexes, all of which may help cause GI phase arrest. Constitutive activation of the PI3K/Akt kinases occur in human leukemias. FLT3, VEGF, and BCR-ABL mediate their activities via mTOR. New rapamycin analogs including CCI- 779, RAD001, and AP23573, are entering clinical studies for patients with hematologic malignancies.

Keywords: mTOR, leukemia, phosphatidylinositol 3' kinase, AKT, CCI-779, RAD001, AP23573

Rights & Permissions Print Export Cite as
© 2023 Bentham Science Publishers | Privacy Policy